GSK to buy HIV drugs from Bristol-Myers Squibb for initial $350 mln
Advertisement
London: Pharmaceutical group GlaxoSmithKline said its majority-owned HIV drugs business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million.
GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth.
The British company is reviving its position in HIV treatment as part of its strategy to return to earnings growth in 2016.
It used to dominate the market but ViiV's 2014 sales of 1.5 billion pounds ($2.3 billion) were less than a quarter of the HIV revenue generated by market leader Gilead Sciences.
ViiV will pay an initial $317 million to buy late-stage HIV drug candidates from Bristol-Myers, including a phase III development treatment fostemsavir, plus $33 million for its preclinical assets.
Both deals are subject to a further payment of over $500 million dependent on commercial milestones being met.
GSK said the assets being acquired complemented ViiV's existing portfolio and could be used in combination therapies.
HIV is often treated by mixing at least three medicines together because of the ability of the virus that causes AIDS to mutate and become drug-resistant.
"The addition of two potential first-in-class late-stage treatments and several promising early clinical development programmes strengthens ViiV Healthcare's pipeline and provides us with further new opportunities for growth," said GSK's chief strategy officer David Redfern, who is also chairman of ViiV.
Demand for HIV drugs is helping GSK replace declining sales of its market-leading respiratory medicine Advair is in decline.
GSK said the acquisitions would provide ViiV Healthcare, its HIV unit in which Pfizer and Shionogi are junior partners, with new opportunities for growth.
The British company is reviving its position in HIV treatment as part of its strategy to return to earnings growth in 2016.
It used to dominate the market but ViiV's 2014 sales of 1.5 billion pounds ($2.3 billion) were less than a quarter of the HIV revenue generated by market leader Gilead Sciences.
ViiV will pay an initial $317 million to buy late-stage HIV drug candidates from Bristol-Myers, including a phase III development treatment fostemsavir, plus $33 million for its preclinical assets.
Both deals are subject to a further payment of over $500 million dependent on commercial milestones being met.
GSK said the assets being acquired complemented ViiV's existing portfolio and could be used in combination therapies.
HIV is often treated by mixing at least three medicines together because of the ability of the virus that causes AIDS to mutate and become drug-resistant.
"The addition of two potential first-in-class late-stage treatments and several promising early clinical development programmes strengthens ViiV Healthcare's pipeline and provides us with further new opportunities for growth," said GSK's chief strategy officer David Redfern, who is also chairman of ViiV.
Demand for HIV drugs is helping GSK replace declining sales of its market-leading respiratory medicine Advair is in decline.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.